Abecma
Payments companies reported to CMS as associated with Abecma. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Abecma, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Abecma
These are the largest totals companies reported as associated with Abecma. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Robert Vescio | West Hollywood, CA | Hematology & Oncology | $53,610.62 |
| George Nahas | Miami, FL | Hematology & Oncology | $45,129.67 |
| Omar Castaneda Puglianini | Tampa, FL | Medical Oncology | $21,835.93 |
| Abraham Kanate | Morgantown, WV | Hematology & Oncology | $20,888.77 |
| Amany Keruakous | Augusta, GA | Hematology & Oncology | $14,821.01 |
| Doris Hansen | Tampa, FL | Hematology (Internal Medicine) | $12,727.87 |
| Mojtaba Akhtari | Omaha, NE | Hematology & Oncology | $12,188.92 |
| Fabio Petrocca | Boston, MA | Medical Oncology | $12,108.91 |
| Rafat Abonour | Indianapolis, IN | Hematology (Internal Medicine) | $10,888.39 |
| Suzanne Fanning | Greenville, SC | Hematology & Oncology | $9,291.29 |
Prescribed Abecma?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.